Teriflunomide Shows Significant Reduction of Plasma Neurofilament … – Neurology Live

Related Articles:

• The road ahead: 2022 January 20, 2022 # # # # The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’ therapies for Parkinson’s.  It is an exercise in managing expectations as well as discussing what research events are scheduled for the next year so that we can keep…
• The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
• A Graph of Your Daily Level of Exogenous Levodopa December 27, 2022 “The greatest achievement is to outperform yourself.” Denis Waitley “Sometimes, carrying on, just carrying on, is the superhuman achievement.” Albert Camus Introduction: Have you been taking carbidopa/levodopa to treat your Parkinson’s? Are you experiencing any off-on periods? Do you have any dyskinesia? Do you think it’s time to change your dosing pattern or the timing of when you take your…
• Monthly Research Review – May 2021 May 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during May 2021. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
• Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration December 26, 2022 Brain. 2022 Dec 27:awac407. doi: 10.1093/brain/awac407. Online ahead of print.ABSTRACTBlood-based biomarkers for amyloid beta and phosphorylated tau show good diagnostic accuracies and agreements with their corresponding CSF and neuroimaging biomarkers in the amyloid/tau/neurodegeneration [A/T/(N)] framework for Alzheimer's disease. However, the blood-based neurodegeneration marker neurofilament light is not specific to Alzheimer's disease while total-tau shows lack of correlation with CSF total-tau.…
• Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration December 26, 2022 Brain. 2022 Dec 27:awac407. doi: 10.1093/brain/awac407. Online ahead of print.ABSTRACTBlood-based biomarkers for amyloid beta and phosphorylated tau show good diagnostic accuracies and agreements with their corresponding CSF and neuroimaging biomarkers in the amyloid/tau/neurodegeneration [A/T/(N)] framework for Alzheimer's disease. However, the blood-based neurodegeneration marker neurofilament light is not specific to Alzheimer's disease while total-tau shows lack of correlation with CSF total-tau.…
• Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration December 26, 2022 Brain. 2022 Dec 27:awac407. doi: 10.1093/brain/awac407. Online ahead of print.ABSTRACTBlood-based biomarkers for amyloid beta and phosphorylated tau show good diagnostic accuracies and agreements with their corresponding CSF and neuroimaging biomarkers in the amyloid/tau/neurodegeneration [A/T/(N)] framework for Alzheimer's disease. However, the blood-based neurodegeneration marker neurofilament light is not specific to Alzheimer's disease while total-tau shows lack of correlation with CSF total-tau.…
• Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration December 26, 2022 Brain. 2022 Dec 27:awac407. doi: 10.1093/brain/awac407. Online ahead of print.ABSTRACTBlood-based biomarkers for amyloid beta and phosphorylated tau show good diagnostic accuracies and agreements with their corresponding CSF and neuroimaging biomarkers in the amyloid/tau/neurodegeneration [A/T/(N)] framework for Alzheimer's disease. However, the blood-based neurodegeneration marker neurofilament light is not specific to Alzheimer's disease while total-tau shows lack of correlation with CSF total-tau.…
• Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration December 26, 2022 Brain. 2022 Dec 27:awac407. doi: 10.1093/brain/awac407. Online ahead of print.ABSTRACTBlood-based biomarkers for amyloid beta and phosphorylated tau show good diagnostic accuracies and agreements with their corresponding CSF and neuroimaging biomarkers in the amyloid/tau/neurodegeneration [A/T/(N)] framework for Alzheimer's disease. However, the blood-based neurodegeneration marker neurofilament light is not specific to Alzheimer's disease while total-tau shows lack of correlation with CSF total-tau.…
• 2020: Year in Review January 1, 2021 # # # # In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2020. Month-by-month we will briefly discuss some of the major pieces of research/ announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies…
• Words with Hope December 8, 2021 “There is no medicine like hope, no incentive so great, and no tonic so powerful as expectation of something better tomorrow.” Orison Swett Marden “Hope is a waking dream.” Aristotle Introduction: Over the years, I have used blog posts about a specific word, feeling, or emotion. A frequent word used a lot here is the word ‘hope’. To some, hope may…
• Neurofilament light chain is increased in the parahippocampal cortex and associates with pathological hallmarks in Parkinson's disease dementia January 19, 2023 Transl Neurodegener. 2023 Jan 20;12(1):3. doi: 10.1186/s40035-022-00328-8.ABSTRACTBACKGROUND: Increased neurofilament levels in biofluids are commonly used as a proxy for neurodegeneration in several neurodegenerative disorders. In this study, we aimed to investigate the distribution of neurofilaments in the cerebral cortex of Parkinson's disease (PD), PD with dementia (PDD) and dementia with Lewy bodies (DLB) donors, and its association with pathology load…
• Neurofilament light chain is increased in the parahippocampal cortex and associates with pathological hallmarks in Parkinson's disease dementia January 19, 2023 Transl Neurodegener. 2023 Jan 20;12(1):3. doi: 10.1186/s40035-022-00328-8.ABSTRACTBACKGROUND: Increased neurofilament levels in biofluids are commonly used as a proxy for neurodegeneration in several neurodegenerative disorders. In this study, we aimed to investigate the distribution of neurofilaments in the cerebral cortex of Parkinson's disease (PD), PD with dementia (PDD) and dementia with Lewy bodies (DLB) donors, and its association with pathology load…
• Neurofilament light chain level in plasma extracellular vesicles and Parkinson's disease. December 19, 2020 Related ArticlesNeurofilament light chain level in plasma extracellular vesicles and Parkinson's disease. Ther Adv Neurol Disord. 2020;13:1756286420975917 Authors: Chung CC, Chan L, Chen JH, Bamodu OA, Hong CT Abstract Background: Neurofilament light chain (NfL) is essential for axonal maintenance and reflects neuronal damage. Extracellular vesicles (EVs), especially exosomes, secreted by cells into the blood, are emerging as novel biomedical research…
• April 28, 2019 - Parkinson’s Weekly Update April 27, 2019 Weekly Update - Spine tingling implants help restore walking ability for housebound patients; young blood infusions aren’t just for vampires any more; brain implants decode and synthesize speech; a health insurer includes coverage for a Parkinson’s Boxing program; Deep Brain Stimulation info;  top Parkinson’s blogs; UK GDNF Trial Follow-up; Parkinson’s exercise programs in the news last week; and more.
• Assessing Plasma Levels of α-Synuclein and Neurofilament Light Chain by Different Blood Preparation Methods December 3, 2021 Front Aging Neurosci. 2021 Nov 8;13:759182. doi: 10.3389/fnagi.2021.759182. eCollection 2021.ABSTRACTThe potential biomarkers of Parkinson's disease are α-synuclein and neurofilament light chain (NFL). However, inconsistent preanalytical preparation of plasma could lead to variations in levels of these biomarkers. Different types of potassium salts of EDTA and different centrifugation temperatures during plasma preparation may affect the results of α-synuclein and NFL measurements.…
• Assessing Plasma Levels of α-Synuclein and Neurofilament Light Chain by Different Blood Preparation Methods December 3, 2021 Front Aging Neurosci. 2021 Nov 8;13:759182. doi: 10.3389/fnagi.2021.759182. eCollection 2021.ABSTRACTThe potential biomarkers of Parkinson's disease are α-synuclein and neurofilament light chain (NFL). However, inconsistent preanalytical preparation of plasma could lead to variations in levels of these biomarkers. Different types of potassium salts of EDTA and different centrifugation temperatures during plasma preparation may affect the results of α-synuclein and NFL measurements.…
• Assessing Plasma Levels of α-Synuclein and Neurofilament Light Chain by Different Blood Preparation Methods December 3, 2021 Front Aging Neurosci. 2021 Nov 8;13:759182. doi: 10.3389/fnagi.2021.759182. eCollection 2021.ABSTRACTThe potential biomarkers of Parkinson's disease are α-synuclein and neurofilament light chain (NFL). However, inconsistent preanalytical preparation of plasma could lead to variations in levels of these biomarkers. Different types of potassium salts of EDTA and different centrifugation temperatures during plasma preparation may affect the results of α-synuclein and NFL measurements.…
• Assessing Plasma Levels of α-Synuclein and Neurofilament Light Chain by Different Blood Preparation Methods December 3, 2021 Front Aging Neurosci. 2021 Nov 8;13:759182. doi: 10.3389/fnagi.2021.759182. eCollection 2021.ABSTRACTThe potential biomarkers of Parkinson's disease are α-synuclein and neurofilament light chain (NFL). However, inconsistent preanalytical preparation of plasma could lead to variations in levels of these biomarkers. Different types of potassium salts of EDTA and different centrifugation temperatures during plasma preparation may affect the results of α-synuclein and NFL measurements.…
• Assessing Plasma Levels of α-Synuclein and Neurofilament Light Chain by Different Blood Preparation Methods December 3, 2021 Front Aging Neurosci. 2021 Nov 8;13:759182. doi: 10.3389/fnagi.2021.759182. eCollection 2021.ABSTRACTThe potential biomarkers of Parkinson's disease are α-synuclein and neurofilament light chain (NFL). However, inconsistent preanalytical preparation of plasma could lead to variations in levels of these biomarkers. Different types of potassium salts of EDTA and different centrifugation temperatures during plasma preparation may affect the results of α-synuclein and NFL measurements.…
• Assessing Plasma Levels of α-Synuclein and Neurofilament Light Chain by Different Blood Preparation Methods December 3, 2021 Front Aging Neurosci. 2021 Nov 8;13:759182. doi: 10.3389/fnagi.2021.759182. eCollection 2021.ABSTRACTThe potential biomarkers of Parkinson's disease are α-synuclein and neurofilament light chain (NFL). However, inconsistent preanalytical preparation of plasma could lead to variations in levels of these biomarkers. Different types of potassium salts of EDTA and different centrifugation temperatures during plasma preparation may affect the results of α-synuclein and NFL measurements.…
• Monthly Research Review: January 2022 January 31, 2022 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during January 2022. The post is divided into 10 parts based on the type of research: Top 6 pieces of Parkinson’s news Articles of general interest Basic biology…